Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma

Bruton’s tyrosine kinase (BTK) is a proven target in mantle cell lymphoma (MCL), an aggressive subtype of non-Hodgkin lymphoma. However, resistance to BTK inhibitors is a major clinical challenge. We here report that MALT1 is one of the top overexpressed genes in ibrutinib-resistant MCL cells, while...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Vivian Changying, Liu, Yang, Lian, Junwei, Huang, Shengjian, Jordan, Alexa, Cai, Qingsong, Lin, Ruitao, Yan, Fangfang, McIntosh, Joseph, Li, Yijing, Che, Yuxuan, Chen, Zhihong, Vargas, Jovanny, Badillo, Maria, Bigcal, John Nelson, Lee, Heng-Huan, Wang, Wei, Yao, Yixin, Nie, Lei, Flowers, Christopher R., Wang, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9888382/
https://www.ncbi.nlm.nih.gov/pubmed/36719376
http://dx.doi.org/10.1172/JCI165694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9888382/
https://www.ncbi.nlm.nih.gov/pubmed/36719376
http://dx.doi.org/10.1172/JCI165694

Ejemplares similares